You just read:

Phase III Results: Once-daily tiotropium Significantly Increases Time to First Severe Exacerbation and Reduces the Risk of Exacerbations in Asthma Patients Still Symptomatic Despite ICS/LABA Treatment

News provided by

Boehringer Ingelheim Limited

03 Sep, 2012, 09:51 BST